The Smart Investor
    Facebook Instagram
    Thursday, July 23
    Facebook Instagram LinkedIn
    The Smart Investor
    • Home
    • About
      • About Us
      • Careers
    • Smart Investing
      • Getting Started
      • Investing Strategy
      • Smart Analysis
      • Smart Reads
    • US Stocks
    • Special Free Reports!
    • As Featured on BT
    • Our Services
      • Our Services
      • Subscribe now!
    • Login
    • Cart
    The Smart Investor
    Home»Growth Stocks»4 US Stocks Hitting 52-Week Lows: Can Their Share Prices Stage a Rebound?
    Growth Stocks

    4 US Stocks Hitting 52-Week Lows: Can Their Share Prices Stage a Rebound?

    These four stocks are engulfed by the bearish sentiment that has seen their share prices hit a year-low. Can they recover any time soon?
    Royston Y.By Royston Y.August 24, 2023Updated:August 25, 20235 Mins Read
    Facebook Twitter LinkedIn Email WhatsApp
    Image credit: Estee Lauder Companies Website
    Share
    Facebook Twitter LinkedIn Email WhatsApp

    It is never easy to see your stocks getting battered.

    Experiencing share price volatility is, however, part and parcel of investing.

    Lower share prices are not always a bad thing.

    It could mean a great opportunity to scoop up shares on the cheap when other investors are feeling bearish.

    Companies sometimes encounter temporary problems that result in lower revenue, profits, and cash flows, resulting in their share prices getting hammered.

    If the business retains its quality, it can eventually overcome these obstacles and post better growth.

    We profile four US stocks that recently touched their 52-week lows to see if they could stage a meaningful rebound.

    Doximity Inc (NYSE: DOCS)

    Doximity is a leading digital platform for US medical professionals and its members include over 80% of US physicians across various specialities and practice areas.

    The company’s share price slid by nearly 29% year-to-date and recently hit a 52-week low of US$21.85.

    Doximity released its fiscal 2024’s first quarter (1Q FY2024) results ending 30 June 2023 recently.

    It was a good set of earnings with revenue rising 19.7% year on year to US$108.5 million and net profit climbing nearly 27% year on year to US$28.4 million.

    The software company also has very low capital expenditure requirements, allowing it to generate a positive free cash flow of US$55.6 million, 30% above the level generated a year ago.

    However, investors were concerned that Doximity announced a 10% cut in its workforce and downgraded its revenue guidance for FY2024.

    The company is facing economic pressures amid slowing sales from its pharmaceutical customers.

    Doximity will incur a restructuring charge of US$8 to US$10 million to be recognised in 2Q FY2024.

    CVS Health Corp (NYSE: CVS)

    CVS Health is a health solutions company that helps its customers to manage their health conditions, stay compliant with medication, and access affordable healthcare services.

    The company’s share price has skidded to a 52-week low of US$64.62 and is down nearly 28% year-to-date.

    CVS Health reported a mixed set of earnings for its fiscal 2023’s first half (1H 2023).

    Revenue increased by 10.6% year on year to US$174.2 billion but operating and net profit fell by 18.7% and 25% year on year to US$6.7 billion and US$4 billion, respectively.

    Free cash flow, however, surged by 56% year on year to US$11.8 billion for 1H 2023 and the healthcare company paid out a dividend of US$1.21, 10% higher than the prior year.

    Like Doximity, CVS Health also announced a layoff of 5,000 employees to cut costs earlier this month.

    In addition, Blue Shield of California, a mutual benefit corporation, dropped CVS Health as its service provider and tied up with Amazon Pharmacy instead.

    Sea Limited (NYSE: SE)

    Sea Limited is a Singapore-based company with businesses in digital entertainment (Garena), e-commerce (Shopee), and digital financial services (SeaMoney).

    Sea’s share price has plunged 31% year-to-date and touched a year-low of US$36.48.

    The company’s recent second quarter 2023 (2Q 2023) results saw growth for Shopee but a decline in revenue for its gaming division.

    E-commerce marketplace revenue jumped 28% year on year to US$1.9 billion for 2Q 2023.

    Digital entertainment, though, saw revenue slip to US$529.4 million for the quarter compared with US$539.7 million a year ago.

    Although quarterly active users grew 11% quarter-on-quarter, the division still posted a 12.1% year on year drop in users to 544.5 million.

    Bookings also continued to dip to US$443.1 million for 2Q 2023, down 4% quarter-on-quarter.

    Shopee has communicated its goal of boosting investments to better compete, leading to worries over losses incurred in future quarters.

    The company had reported three consecutive quarters of profitability but investors fret that it will fall back to losses as it cited the need to ramp up spending.

    Estee Lauder Companies Inc (NYSE: EL)

    Estee Lauder is a leading manufacturer and retailer of quality skincare, makeup, fragrance and hair care products.

    The company’s well-known brands include Estee Lauder, Clinique, Bobbi Brown, and Tom Ford which are sold in around 150 countries.

    The cosmetics company’s shares have plunged by 41% year-to-date and recently touched a 52-week low of US$147.18.

    Estee Lauder reported a weak set of earnings for its fiscal 2023 (FY2023) ending 30 June.

    Sales declined by 10% year on year to US$15.9 billion while operating profit fell 52% year on year to US$1.5 billion as administrative expenses dropped by less than its revenue decline.

    Net profit plunged 58% year on year to US$1 billion.

    The company also saw its free cash flow for FY2023 turn negative after posting a positive free cash flow of US$2 billion for FY2022.

    Management has forecast sales and net profit that was below estimates as it encountered a slower-than-expected rebound for its travel retail segment in Asia.

    Coupled with waning demand in the US because of high inflation and a weak recovery in China, Estee Lauder’s sales look to remain under pressure in the near term.

    Are we really ready to live in a world with AI that could potentially take over our jobs? Check out our latest Special Free Report on this fascinating topic. We cover the latest developments in AI and how they could impact your life and investments. Click here to download a copy now.

    Follow us on Facebook and Telegram for the latest investing news and analyses!

    Disclosure: Royston Yang does not own shares in any of the companies mentioned.

    Yahoo
    Share. Facebook Twitter LinkedIn Email WhatsApp

    Related Posts

    Mapletree Industrial Trust (MIT)

    3 REITs That Could Boost Dividends as Borrowing Costs Ease

    July 22, 2026

    Watch the Small-Caps Event Recording: Hidden Gems Punching Above Their Weight

    July 22, 2026

    As the Stock Market Grows Bigger, Our Heads Shouldn’t

    July 22, 2026
    Facebook Instagram LinkedIn Telegram
    • Careers
    • Disclaimer & Privacy Policy
    • Advertising & Media Enquiries
    • Subscription Terms of Service
    © 2026 The Smart Investor. All Rights Reserved. The Smart Investor, thesmartinvestor.com.sg, an investment education website managed by The Investing Hustle Pte Ltd (Company Reg No. 201933459Z) is not licensed or otherwise regulated by the Monetary Authority of Singapore, and in particular, is not licensed or regulated to carry on business in providing any financial advisory service. Accordingly, any information provided on this site is meant purely for informational and investor educational purposes and should not be relied upon as financial advice. No information is presented with the intention to induce any reader to buy, sell, or hold a particular investment product or class of investment products. Rather, the information is presented for the purpose and intentions of educating readers on matters relating to financial literacy and investor education. Accordingly, any statement of opinion on this site is wholly generic and not tailored to take into account the personal needs and unique circumstances of any reader. The Smart Investor does not recommend any particular course of action in relation to any investment product or class of investment products. Readers are encouraged to exercise their own judgment and have regard to their own personal needs and circumstances before making any investment decision, and not rely on any statement of opinion that may be found on this site.

    Type above and press Enter to search. Press Esc to cancel.